Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GILD

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

3 Undervalued Healthcare Stocks With High Potential

3 Undervalued Healthcare Stocks With High Potential

The healthcare sector is expected to grow rapidly due to the growing need for precision drugs, the rising elderly population, government initiatives, and increasing chronic diseases. Against this backdrop, investors could consider buying fundamentally strong, undervalued healthcare stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD). Read…

3 Biotech Stocks With Potential Breakthroughs Emerging

3 Biotech Stocks With Potential Breakthroughs Emerging

The biotech industry's future is promising, driven by advanced technologies like AI and VR, the rising popularity of personalized treatments, and increased R&D spending. Let's analyze the investment prospects of biotech stocks Amgen (AMGN), United Therapeutics (UTHR), and Gilead Sciences (GILD) as potential breakthroughs emerge. Read more.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

3 A-Rated Biotech Stocks for Long-Term Investors

The future of the biotech industry appears bright, driven by extensive usage across healthcare and agriculture alongside rapid advancements in technology. Thus, top biotech stocks Entrada Therapeutics (TRDA), Exelixis (EXEL), and Gilead Sciences (GILD) could be solid buys for long-term investors. These stocks are rated A (Strong Buy) in our…

Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports…

3 Biotech Stocks to Invest In Right Now for Long-Term Gains

With the rapidly growing demand for personalized medicine, innovative solutions, and recent developments like AI in drug discovery, the biotech industry's prospects appear robust. Thus, quality biotech stocks Vertex Pharmaceuticals (VRTX), SIGA Technologies (SIGA), and Gilead Sciences (GILD) could be ideal candidates to buy now. Read more….

inkl

Read news from The Economist, FT, and more,
with one subscription

4 A-Rated Biotech Stocks Sparking Investor Interest

4 A-Rated Biotech Stocks Sparking Investor Interest

The biotech industry is rapidly evolving thanks to the surging biopharma M&A activity and incorporation of new technological trends like AI and gene editing. Given this backdrop, quality biotech stocks Gilead Sciences (GILD), Equillium (EQ), Incyte Corporation (INCY), and Jazz Pharmaceuticals plc (JAZZ), rated A (Strong Buy) overall in our…

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now?

This Week's Biotech Stock Star Performers

This Week's Biotech Stock Star Performers

The biotech industry is poised for robust growth thanks to the increasing demand for personalized treatments, the rise in chronic diseases, a rapidly aging population, the adoption of advanced technologies, and government initiatives. Therefore, to capitalize on the industry’s growth prospects, one could consider buying fundamentally strong biotech stocks Genmab…

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

Top 3 Biotech Picks for Profits and Value

Top 3 Biotech Picks for Profits and Value

The biotechnology industry thrives with innovation, along with the pharmacy market's expansion powered by digitalization. Hence, it might be ideal to buy fundamentally solid biotech stocks Merck KGaA (MKKGY), Entrada Therapeutics (TRDA), and Gilead Sciences (GILD) for profits and value. Read more to find out….

3 Biotech Stock Gems Bursting With Buy Opportunities

3 Biotech Stock Gems Bursting With Buy Opportunities

The biotech industry is well poised to flourish, buoyed by its commitment to innovation and potential for groundbreaking discoveries. Thus, investing in the shares of three fundamentally solid biotech companies, Foghorn Therapeutics (FHTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD), might be prudent. Continue reading….

Stock Market Today: Stocks Build on Broad-Based Gains

Stock Market Today: Stocks Build on Broad-Based Gains

A heavy week of earnings and data ahead couldn't spoil the market's record-setting Monday mood.

Get all your
news in one place.

100's of premium titles.
One news app.

Top 3 Biotech Stocks for Weekly 2024 Profits

The biotech industry is growing as a result of steady demand and tech advancements. So, it could be wise to invest in quality biotech stocks Theratechnologies (THTX), Gilead Sciences (GILD), and Exelixis (EXEL) for weekly gains. Read on.

Top 4 Biotech Stock Buys for 2024 Gains

The biotech industry's dynamic growth, spurred by government backing and technological advances, addresses rising disease challenges and propels advancements in healthcare. Hence, fundamentally strong biotech stocks Gilead Sciences (GILD), Incyte Corporation (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be solid investments for upcoming year gains. Read more….

Are These the Top 3 Biotech Stocks Set for Year-End Profits?

As the biotech industry experiences robust growth, driven by innovation, government initiatives, and global market expansion, let us delve into fundamentally solid biotech stocks Gilead Sciences (GILD), Exelixis (EXEL), and Incyte Corp (INCY) to evaluate their year-end profitability potential. Read more to find out….

I’ve Got 5 Stocks and 5 DTEs: Which Call Should I Buy?

Wednesday’s unusual options activity had multiple stocks with two or more calls expiring on the same day. Five stocks caught my interest. Only one of the calls is worth buying.

Get all your
news in one place.

100's of premium titles.
One news app.

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

Using Market Volatility to Your Advantage: Selling a GILD Put Option Before Earnings

A trader selling the November 10th, $76-strike put on GILD would receive around $105 into their account, which would be theirs to keep.

4 Promising Biotech Stocks for Smart Investment Strategies

The biotechnology industry is flourishing due to the recent strides in drug formulation, technological advancements, and unwavering government support. Given this backdrop, promising biotech stocks United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD) present smart investment options to garner significant returns. Read on….

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks?

As the biotech industry reaches new heights with innovation and the accessibility of big data, let us analyze whether biotech stocks Bionano Genomics and Gilead Sciences are a Buy, Hold, or Sell.

1 … 3 4 5 6

People

Kritika SarmahHer

Dipanjan BanchurSince

Steve Reitmeister

Neha PanjwaniFrom

Steven AdamsAfter

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

394,012 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play